Breast cancer test gave Atossa a revenue boost in Q2

08/16/2013 | GenomeWeb Daily News (free registration)

Atossa Genetics posted $326,078 in revenue during the second quarter, up from $223,097 in the same period last year. The increase was fueled by sales of the company's ForeCYTE Breast Health Test, which stratifies patients' breast cancer risk based on mammary aspirate samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC